Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/614822


Czech Republic Pharmaceuticals and Healthcare Report Q3 2008


Description: This report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry.

The Czech drug market should grow at a reasonable rate over BMI’s forecast period, with drug expenditure reaching a value of US$3.78bn by 2012. Although growth should slow in the short-term, it should pick up towards the end of the forecast period, driven by a strong underlying economic performance and growing out-of-pocket spending. Fiscal austerities, although lauded by the OECD, should have a deflationary impact on the Czech drug sector with many drug makers looking to expand abroad in order to secure revenues.

In terms of company activity, the biggest news in Q308 has been the takeover bid for generic drug maker Zentiva by the country’s richest businessman, Petr Kellner. Zentiva is currently mulling over the bid, which valued the company at CZK950 (US$58.2) per share. Meanwhile, Zentiva has made the news in a different way recently after it announced that it was to develop a generic form of Pfizer’s erectile dysfunction (ED) drug Viagra (sildenafil) to be sold in its existing markets when the patent expires in 2011.

Meanwhile, the country’s health reforms, which finally came into being in January 2008, are continuing to cause controversy. Most political parties, including the CDDS, the Communists (KSCM) and the Christian Democrats (KDU-CSL) have reservations about the scheme. These parties vary in their stance on whether health fees should be completely abolished or not; however, a common theme is that groups such as the very young, elderly and socially disadvantaged should be exempt from paying. A poll carried out by local newspaper Lidove Noviny in March 2008 supported this view, with three quarters of Czechs wanting certain social groups to be exempt from payments.

The Czech Republic remains in second place in the CEE regional Business Environment Ranking. The United States Trade Representative (USTR) is concerned about the country’s intellectual property accords, however BMI believes that a restructuring of the State Institute for Drug Control (SUKL) will have benefits for the drug market in general.


Contents: Executive Summary 5

Czech Republic Pharmaceuticals And Healthcare Industry SWOT 6
Czech Republic Political SWOT 7
Czech Republic Economic SWOT 7
Czech Republic Business Environment SWOT 8
Pharmaceutical Business Environment Ratings 9
Table: Central And Eastern Europe Pharmaceutical Business Environment Ratings 9

Limits To Potential Returns 10
Risks To Realisation Of Returns 10

Czech Republic – Market Summary 11
Regulatory Regime 12
Intellectual Property Environment 13
Pricing And Reimbursement Issues 14
Pharmacy Sector 16
Hospital Sector 17
Healthcare Sector 19
Opposition To Health Fees 22

Research And Development Sector 23
Industry Forecast Scenario 24
Overall Market Forecast 24
Table: Czech Republic’s Drug Market Forecast Indicators, 2005-2012 24
Key Growth Factors – Industry 25
Table: Czech Republic’s Health Expenditure Indicators, 2005-2012 26
Key Growth Factors – Macroeconomic 27
Table: Czech Republic – Economic Activity 28
Patented Drug Market Forecast 29
Table: Patented Drugs Market Indicators, 2006-2012 (US$mn unless otherwise stated) 30
OTC Market Forecasts 31
Table: OTC Drugs Market Indicators, 2005-2012 (US$mn unless otherwise stated) 31
Generics Market Forecasts 32
Table: Czech Republic’s Generics Market Forecast 32
Export/Import Forecasts 33
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2005-2012 (US$mn) 33
Other Healthcare Data Forecasts 34
Table: Socio-Demographic Indicators 34
Key Risks To BMI’s Forecast Scenario 35

Competitive Landscape 36
Wholesale 42
Retail 42
Company Monitor 45
Multinational Companies 45
AstraZeneca 45
Bristol-Myers Squibb 46
Sanofi-Aventis 47
Walmark 49
Local Company 51
Zentiva (incorporating Sicomed) 51

BMI Forecast Modelling 54
How We Generate Our Pharmaceutical Industry Forecasts 54
Pharmaceutical Industry 55
Pharmaceutical Business Environment Ratings Methodology 55
Ratings Overview 55
Table: Pharmaceutical Business Environment Indicators 56
Weighting 57
Table: Weighting Of Components 57

Sources 57


Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Sanofi-Aventis - Walmark - Local Company - Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/614822

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 27/11/2009 09:50:56
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q3 2008
Web Address:
http://www.researchandmarkets.com/reports/614822
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 27/11/2009 09:50:56

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)